Table 1.

Inclusion criteria for studies

Population	Populations at substantial risk of HIV, including men who have sex with men, serodiscordant heterosexual couples, heterosexuals and people who inject drugs
Intervention	Oral tenofovir-containing PrEP
Comparator	Placebo, no treatment or alternative oral PrEP medication/dosing schedule
Outcomes	Primary outcome: relative risk of HIV infection  Secondary outcomes:  Adherence to PrEP.  Adverse events.  Incidence of other STIs and behaviour change associated with PrEP use.  Viral drug mutations among those who contract HIV.
Studies	RCTs

PrEP, pre-exposure prophylaxis; RCT, randomised controlled trial; STI, sexually transmitted infection.